Sep 16 |
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
|
Sep 6 |
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
|
Aug 15 |
Immatics Second Quarter 2024 Earnings: Beats Expectations
|
Aug 13 |
Immatics GAAP EPS of -€0.17, revenue of €18.8M
|
Aug 13 |
Immatics Announces Second Quarter 2024 Financial Results and Business Update
|
Jul 31 |
Immatics Appoints Alise Reicin to Board of Directors
|
Jul 25 |
Investors in Immatics (NASDAQ:IMTX) have seen returns of 24% over the past five years
|
Jul 18 |
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
|
Jun 14 |
Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns
|
May 21 |
Here's Why We're Not Too Worried About Immatics' (NASDAQ:IMTX) Cash Burn Situation
|